Conference Programme

You will find the preliminary programme of the conference on February, 24th here. 

Time Title
09:00 – 09:30 Registration
09:30 – 09:45 Welcome address
Sir Sebastian Wood KCMG, British Ambassador to Germany
Keynote Session
09:45 – 10:10 Keynote: Why thinking about novel antimicrobials
Timothy Jinks, Wellcome Trust, UK (requested)
10:10 – 10:30 Stimulating innovation: novel approaches to incentivising antibacterial R&D
David Findlay, Deputy Coordinator Drive-AB/GSK, UK
10:30 – 10:50

Funding the research and development of novel antibiotics:  the perspective of a startup company
Nicholas Benedict, Co-Founder & CEO, Allecra, GER

10:50 – 11:10 Coffee Break
Session "Market access in the era of AMR - bringing ideas to the patients"

Session “SMEs to tackle AMR”

Chair: Philippe Villain-Guillot, CEO, Nosopharm

- Leonie de Best, CBO, Madam Therapeutics, NL
- David Cook, CSO, Blueberry Therapeutics, UK
- Heather Fairhead, CEO, PhicoTherapeutics, UK
- Marc Lemonnier, CEO, Antabio, F

11:10 – 11:40 IP & Regulation: Patent strategies to meet the challenge
of AMR
Ute Kilger (Partner) & Heinz Goddar (Partner), Boehmert & Boehmert, GER
11:40 – 12:00 Clinical decision making: The relevance of new methods for antimicrobial susceptibility testing,
Hajo Grundmann, University of Groningen, Member of EUCAST Subcommittee, NL 
12:00 – 12:20

Investing in innovation: Innovative financing tools to incentivise R&D in the antimicrobials field, Christopher Egerton-Warburton, Fund Manager and Founding Partner of Lion's Head Global Partner and Member of Expert Advisory Bord, Global AMR Innovation Fund 

12:20 – 12:40 Economics: Distribution strategies, funding and re-imbursement models for antimicrobials
Elias Mossialos, London School of Economics & LSE Health, UK (requested)
12:40 – 13:30 Lunch Break
Session “How to create a business case with antimicrobials”

Session: Think beyond – technology highlights from academic research

Chair: Andrew Ullmann, University of Würzburg

- Yves Briers, Ghent University, BE
- Anders Karlén, University of Uppsala, SE 
- Stephan Sieber, Technical University Munich, GER
- Michael McDonough, University of Oxford, UK
- Mark Brönstrup, Helmholtz Centre for Infection Research, GER
- Andreas Peschel, University of Tübingen, GER

 

13:30 – 13:50 Public-private partnerships to accelerate the devlopment of antimicrobial drugs
Peter Jackson, steering group chairman, AMR centre, UK
13:50 – 14:10 Convincing investors of novel antimicrobials
Neil Murray, CEO, RedX Pharma, UK
14:10 – 14:30

The SME perspective
Marc Gitzinger, CEO, BioVersys, CH

14:30 – 15:30

Technology Highlights
- Rasmus Toft-Kehler, CEO, AntibioTx, DK
- Deborah O’Neil, CEO & CSO, NovaBiotics, UK
- Philippe Villain-Guillot, CEO, Nosopharm, F


15:30 – 16:00 Coffee Break
Session “Start-up competition & investors talk”
16:00 – 16:20

Investors talk – Panel Discussion: Developing new antimicrobial agents - a business case for start-ups?
Holger Reithinger, Partner, Forbion Capital Partners, GER/NL
Marc Gitzinger, CEO, BioVersys, CH
Rasmus Toft-Kehler, CEO, AntibioTx, DK
Olivier Litzka, Partner, Edmond de Rothschild, F
Patrick Burgermeister, Partner, BioMedPartners AG, CH

16:20 – 17:20

Start-up pitch: Start-up presentations and award
Auspherix, UK
Centauri Therapeutics, UK (requested)
Eligo Biosciences, F (requested)
Immunethep, P
Oxford Antibiotics, UK (requested)
QureTech Bio, S

17:20 – 17:40 Open discussion and wrap-up: The future of antiinfective R&D
17:40 – 19:00 Networking & reception

Moderator: Peter West, CEO, Academy of Infection Management (AIM)